NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Paclitaxel (PTX) is one of the most effective anticancer agents. In clinical practice, however, high incidences of adverse reactions of the drug, for example, neurotoxicity, myelosuppression, and allergic reactions, have been reported. NK105, a micellar nanoparticle formulation, was developed to overcome these problems and to enhance the antitumour activity of PTX. Via the self-association process, PTX was incorporated into the inner core of the micelle system by physical entrapment through hydrophobic interactions between the drug and the well-designed block copolymers for PTX. NK105 was compared with free PTX with respect to their in vitro cytotoxicity, in vivo antitumour activity, pharmacokinetics, pharmacodynamics, and neurotoxicity. Consequently, the plasma area under the curve (AUC) values were approximately 90-fold higher for NK105 than for free PTX because the leakage of PTX from normal blood vessels was minimal and its capture by the reticuloendothelial system minimised. Thus, the tumour AUC value was 25-fold higher for NK105 than for free PTX. NK105 showed significantly potent antitumour activity on a human colorectal cancer cell line HT-29 xenograft as compared with PTX (P<0.001) because the enhanced accumulation of the drug in the tumour has occurred, probably followed by its effective and sustained release from micellar nanoparticles. Neurotoxicity was significantly weaker with NK105 than with free PTX. The neurotoxicity of PTX was attenuated by NK105, which was demonstrated by both histopathological (P<0.001) and physiological (P<0.05) methods for the first time. The present study suggests that NK105 warrants a clinical trial for patients with metastatic solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The size of polymeric micelles currently in clinical trials are less than 100 nm [6, 7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NK105 exhibited 23% of drug loading with a hydrodynamic size of approx. 90 nm [7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“NK105 is composed of paclitaxel and modified mPEG-b-P(Asp) block copolymer (mPEG = 12,000 g/mol and P(Asp) = 8,000 g/mol) where half of the carboxylic groups P(Asp) block is modified with hydrophobic 4-phenyl-1-butanol to increase its hydrophobicity and improve drug incorporation [7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“Passive targeting is based on the so-called enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles
Savić, R., Luo, L., Eisenberg, A., & Maysinger, D. (2003) · Science · doi:10.1126/science.1078192 · Cited by 1,113
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Block copolymer micelles as vehicles for drug delivery
Kazunori, K., Glenn S., K., Masayuki, Y., Teruo, O., & Yasuhisa, S. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90172-2 · Cited by 877
Self-citationKim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Development of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570
Self-citation
Research works printed but not linked: 1
- 2. Hamaguchi T, Matsumura Y, Shirao Y, Shimada Y, Yamada Y, Muro Y, Okusaka T, Ueno H, Ikeda M, Watanabe N (2003) Phase I study of novel drug delivery system, NK911, a polymer micelle encapsulated doxor- ubicin. Proc Am Soc Clin Oncol 22: 571
Cited by
Items 201–300 of 565
Lipid-based nanoparticles for cancer treatment
Obeid, M. A., Tate, R. J., Mullen, A. B., & Ferro, V. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813687-4.00008-6 · Cited by 89
Li, A., & Zhang, D. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.5b01561 · Cited by 72
The effect of core composition in biodegradable oligomeric micelles as taxane formulations
Carstens, M. G., de Jong, P. H. J. L. F., van Nostrum, C. F., Kemmink, J., Verrijk, R., de Leede, L. G. J., Crommelin, D. T., & Hennink, W. E. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.08.014 · Cited by 81
Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer
Chowdhury, P., Nagesh, P. K. B., Khan, S., Hafeez, B. B., Chauhan, S. C., Jaggi, M., & Yallapu, M. M. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.10.004 · Cited by 70
Huesmann, D., Sevenich, A., Weber, B., & Barz, M. (2015) · Polymer · doi:10.1016/j.polymer.2015.04.070 · Cited by 67
Seo, Y., Schulz, A., Han, Y., He, Z., Bludau, H., Wan, X., Tong, J., Bronich, T. K., Sokolsky, M., Luxenhofer, R., et al. (2015) · Polymers for Advanced Technologies · doi:10.1002/pat.3556 · Cited by 67
Bioactive nanotherapeutic trends to combat triple negative breast cancer
Chowdhury, P., Ghosh, U., Samanta, K., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.037 · Cited by 84
Doxorubicin Conjugate of Poly(Ethylene Glycol)‐Block‐Polyphosphoester for Cancer Therapy
Sun, C., Dou, S., Du, J., Yang, X., Li, Y., & Wang, J. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300091 · Cited by 66
Miki, K., Oride, K., Inoue, S., Kuramochi, Y., Nayak, R. R., Matsuoka, H., Harada, H., Hiraoka, M., & Ohe, K. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.10.005 · Cited by 67
Letchford, K., & Burt, H. M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2002939 · Cited by 64
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
Kamei, T., Kitayama, J., Yamaguchi, H., Soma, D., Emoto, S., Konno, T., Ishihara, K., Ishigami, H., Kaisaki, S., & Nagawa, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01747.x · Cited by 67
Nanoparticle-Mediated Drug Delivery for Treating Melanoma
Mundra, V., Li, W., & Mahato, R. I. (2015) · Nanomedicine · doi:10.2217/nnm.15.111 · Cited by 68
Lu, H., Li, B., Kang, Y., Jiang, W., Huang, Q., Chen, Q., Li, L., & Xu, C. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0256-z · Cited by 63
Intelligent thermoresponsive polymeric micelles for targeted drug delivery
Nakayama, M., & Okano, T. (2006) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(06)50005-x · Cited by 70
Soma, D., Kitayama, J., Konno, T., Ishihara, K., Yamada, J., Kamei, T., Ishigami, H., Kaisaki, S., & Nagawa, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01265.x · Cited by 72
Combinatorial nanomedicines for colon cancer therapy
Anitha, A., Maya, S., Sivaram, A. J., Mony, U., & Jayakumar, R. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1353 · Cited by 62
Takahashi, M., Miki, S., Fujimoto, K., Fukuoka, K., Matsushita, Y., Maida, Y., Yasukawa, M., Hayashi, M., Shinkyo, R., Kikuchi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.14067 · Cited by 67
Targeted delivery of platinum-taxane combination therapy in ovarian cancer
Desale, S. S., Soni, K. S., Romanova, S., Cohen, S. M., & Bronich, T. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.007 · Cited by 61
Han, Y., Kim, D. H., & Pack, S. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211121 · Cited by 83
Cunningham, A. J., Robinson, M., Banquy, X., Chain, J. L., & Zhu, X. X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01091 · Cited by 64
Bio‐inspired functional coacervates: Special Issue: Emerging Investigators
Chen, S., Guo, Q., & Yu, J. (2022) · Aggregate · doi:10.1002/agt2.293 · Cited by 65
Polymeric micelles for cancer therapy: 3 C’s to enhance efficacy
Talelli, M., Rijcken, C. J. F., Hennink, W. E., & Lammers, T. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.003 · Cited by 58
Polymeric nano-micelles: Versatile Platform for Targeted Delivery in Cancer
Mohamed, S. E.-S. H., Parayath, N. N., Taurin, S., & Greish, K. F. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.69 · Cited by 61
Clinical Translation of Self‐Assembled Cancer Nanomedicines
Mi, P., Miyata, K., Kataoka, K., & Cabral, H. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000159 · Cited by 65
Self-citationCancer Nanotherapeutics in Clinical Trials
Lytton‐Jean, A. K. R., Kauffman, K. J., Kaczmarek, J. C., & Langer, R. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4_13 · Cited by 60
Tong, R., Christian, D. A., Tang, L., Cabral, H., Baker, J. R., Kataoka, K., Discher, D. E., & Cheng, J. (2009) · MRS Bulletin · doi:10.1557/mrs2009.118 · Cited by 66
Self-citationNanotechnology-based strategies for combating toxicity and resistance in melanoma therapy
Brys, A. K., Gowda, R., Loriaux, D. B., Robertson, G. P., & Mosca, P. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.01.004 · Cited by 60
Markeb, A. A., El‐Maali, N. A., Sayed, D. M., Osama, A., Abdel-Malek, M. A. Y., Zaki, A. H., Abdel-Wanis, M. E., & Driscoll, J. J. (2016) · International Journal of Breast Cancer · doi:10.1155/2016/7549372 · Cited by 53
Wang, D., Zhou, Y., Li, X., Qu, X., Deng, Y., Wang, Z., He, C., Zou, Y., Jin, Y., & Liu, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b16376 · Cited by 52
Liu, Y., Xu, Q., Liu, P., Ghzaoui, A. E., & Li, S. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.030 · Cited by 61
Clinical Applications of Targeted Nanomaterials
Kumar, A., Shahvej, S., Yadav, P. K., Modi, U., Yadav, A. K., Solanki, R., & Bhatia, D. D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030379 · Cited by 60
The potential of polymeric micelles in the context of glioblastoma therapy
Morshed, R. A., Cheng, Y., Auffinger, B., Wegscheid, M. L., & Lesniak, M. S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00157 · Cited by 56
Zhong, J., Yang, S., Wen, L., & Xing, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.010 · Cited by 49
Developments and future clinical outlook of taxane nanomedicines
Louage, B., Wever, O. D., Hennink, W. E., & Geest, B. G. D. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.027 · Cited by 58
A Brief Review on Advantages of Nano-based Drug Delivery Systems
Hami, Z. (2021) · Annals of Military and Health Sciences Research · doi:10.5812/amh.112274 · Cited by 68
Preparation of Caffeic Acid Phenethyl Ester-Incorporated Nanoparticles and Their Biological Activity
Lee, H. Y., Jeong, Y., Kim, E., Lee, K. D., Choi, S.-H., Kim, Y. J., Kim, D., & Choi, K. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24278 · Cited by 52
Self-assembling polymer systems for advanced treatment of cancer and inflammation
Palao‐Suay, R., Gómez‐Mascaraque, L. G., Aguilar, M. R., Vázquez‐Lasa, B., & Román, J. S. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2015.07.005 · Cited by 54
Lipid-based nanoparticles as drug delivery system for paclitaxel in breast cancer treatment
Marcial, S. P. D. S., Carneiro, G., & Leite, E. A. (2017) · Journal of Nanoparticle Research · doi:10.1007/s11051-017-4042-0 · Cited by 48
Hu, J. Q., He, J., Cao, D., Zhang, M., & Ni, P. (2015) · Polymer Chemistry · doi:10.1039/c5py00023h · Cited by 48
Kim, Y., Pourgholami, M. H., Morris, D. L., Lu, H., & Stenzel, M. H. (2013) · Biomater. Sci. · doi:10.1039/c2bm00096b · Cited by 47
Prevention of paclitaxel-induced neuropathy by formulation approach
Zang, X., Lee, J. B., Deshpande, K., Garbuzenko, O. B., Minko, T., & Kagan, L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.013 · Cited by 47
Rapoport, N. Y., Gupta, R., Kim, Y.-S., & O’Neill, B. E. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.010 · Cited by 47
Biodegradable Stimuli-Responsive Polymeric Micelles for Treatment of Malignancy
Yan, L., & Li, X. D. (2016) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101703160206142821 · Cited by 48
The EPR Effect in Cancer Therapy
Yhee, J. Y., Son, S., Son, S., Joo, M. K., & Kwon, I. C. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7876-8_23 · Cited by 52
Saito, Y., Yasunaga, M., Kuroda, J., Koga, Y., & Matsumura, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00806.x · Cited by 45
Self-citationRehan, F., Ahemad, N., Islam, R. A., Gupta, M., Gan, S. H., & Chowdhury, E. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100984 · Cited by 42
Nanomedicine and versatile therapies for cancer treatment
Shukla, A., & Maiti, P. (2022) · MedComm · doi:10.1002/mco2.163 · Cited by 51
Channa, G. M., Hassan, D., Ruiz-Pulido, G., Pourmadadi, M., Eshaghi, M. M., Behzadmehr, R., Tehrani, F. S., Rahdar, A., Medina, D. I., & Pandey, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104494 · Cited by 50
Magnetic responsive of paclitaxel delivery system based on SPION and palmitoyl chitosan
Mansouri, M., Nazarpak, M. H., Solouk, A., Akbari, S., & Hasani‐Sadrabadi, M. M. (2016) · Journal of Magnetism and Magnetic Materials · doi:10.1016/j.jmmm.2016.07.066 · Cited by 44
Kuramochi, H., Andoh, Y., Yoshii, N., & Okazaki, S. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp906155z · Cited by 43
Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
Yang, D., Yu, L., & Van, S. (2010) · Cancers · doi:10.3390/cancers3010017 · Cited by 49
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems
Viegas, C., Patrício, A. B., Prata, J., Fonseca, L., Macedo, A. S., Duarte, S. O. D., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092363 · Cited by 50
Jiang, D., Mu, W., Pang, X., Liu, Y., Zhang, N., Song, Y., & Garg, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b09946 · Cited by 42
Synthesis and Self-Assembly of RGD-Functionalized PEO-PB Amphiphiles
Zupancich, J. A., Bates, F. S., & Hillmyer, M. A. (2009) · Biomacromolecules · doi:10.1021/bm900149b · Cited by 41
Howard, B., Gao, Z., Lee, S.-W., Seo, M.-H., & Rapoport, N. Y. (2006) · American Journal of Drug Delivery · doi:10.2165/00137696-200604020-00005 · Cited by 43
Intraperitoneal chemotherapy against peritoneal carcinomatosis
Kitayama, J. (2014) · Surgical Oncology · doi:10.1016/j.suronc.2014.03.004 · Cited by 40
Chang, T., Lord, M. S., Bergmann, B., Macmillan, A., & Stenzel, M. H. (2014) · Journal of Materials Chemistry B · doi:10.1039/c3tb21751e · Cited by 38
Kim, Y., Pourgholami, M. H., Morris, D. L., & Stenzel, M. H. (2010) · Macromolecular Bioscience · doi:10.1002/mabi.201000293 · Cited by 44
Emoto, S., Yamaguchi, H., Kishikawa, J., Yamashita, H., Ishigami, H., & Kitayama, J. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02274.x · Cited by 45
Yasunaga, M., Furuta, M., Ogata, K., Koga, Y., Yamamoto, Y., Takigahira, M., & Matsumura, Y. (2013) · Scientific Reports · doi:10.1038/srep03050 · Cited by 41
Self-citationYang, R., Zheng, Y. Z., Shuai, X., Fan, F., He, X., Ding, M.-M., Li, J., Tan, H. S., & Fu, Q. (2020) · Advanced Science · doi:10.1002/advs.201902701 · Cited by 40
Development of Electrochromic Devices
Pawlicka, A. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177821 · Cited by 44
Triggering the fast release of drugs from crosslinked micelles in an acidic environment
Kim, Y., Pourgholami, M. H., Morris, D. L., & Stenzel, M. H. (2011) · Journal of Materials Chemistry · doi:10.1039/c1jm11062d · Cited by 45
Zhang, J., Li, S., & Li, X. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177803 · Cited by 42
Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)–paclitaxel nanoparticles
Van, S., Yu, L., & Yang (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s15839 · Cited by 38
Yamamoto, Y., Hyodo, I., Koga, Y., Tsumura, R., Sato, R., Obonai, T., Fuchigami, H., Furuya, F., Yasunaga, M., Harada, M., et al. (2015) · Cancer Science · doi:10.1111/cas.12645 · Cited by 40
Self-citationMiki, K., Kuramochi, Y., Oride, K., Inoue, S., Harada, H., Hiraoka, M., & Ohe, K. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800449s · Cited by 40
Polomska, A. K., Gauthier, M. A., & Leroux, J. (2016) · Small · doi:10.1002/smll.201602066 · Cited by 39
van Eerden, R. A. G., Mathijssen, R. H. J., & Koolen, S. L. W. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s272529 · Cited by 40
Gou, M., Shi, H., Guo, G. F., Men, K., Zhang, J., Zheng, L., Li, Z., Luo, F., Qian, Z., Zhao, X., et al. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/9/095102 · Cited by 40
Cambón, A., Rey‐Rico, A., Mistry, D., Brea, J. M., Loza, M. I., Attwood, D., Barbosa, S., Alvarez‐Lorenzo, C., Concheiro, Á., Taboada, P., et al. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.056 · Cited by 39
Docetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancer
Borrajo, E., Abellan-Pose, R., Soto, A., García-Fuentes, M., Csaba, N., Alonso, M. J., & Vidal, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.048 · Cited by 40
Nanoparticles for cosmetic use and its application
Chiari‐Andréo, B. G., de Almeida-Cincotto, M. G. J., Oshiro, J. A., Taniguchi, C. Y. Y., Chiavacci, L. A., & Isaac, V. L. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816504-1.00013-2 · Cited by 45
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles
Rijcken, C. J. F., Lorenzi, F. D., Biancacci, I., Hanssen, R., Thewissen, M. M., Hu, Q., Atrafi, F., Liskamp, R. M. J., Mathijssen, R. H. J., Miedema, I. H. C., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114613 · Cited by 39
Barz, M., Armiñán, A., Canal, F., Wolf, F. K., Koynov, K., Frey, H., Zentel, R., & Vicent, M. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.024 · Cited by 44
Novel polymeric micelles for drug delivery: Material characterization and formulation screening
Janas, C., Mostaphaoui, Z., Schmiederer, L., Bauer, J., & Wacker, M. G. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.029 · Cited by 36
Gaucher, G., Poreba, M., Ravenelle, F., & Leroux, J. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20833 · Cited by 46
Delivery of Therapeutics Using Nanocarriers for Targeting Cancer Cells and Cancer Stem Cells
Krishnamurthy, S., Ke, X., & Yang, Y. Y. (2015) · Nanomedicine · doi:10.2217/nnm.14.154 · Cited by 36
Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Raj, R., Mongia, P. R., Sahu, S. K., & Ram, A. (2016) · Current Drug Targets · doi:10.2174/1389450116666150722141607 · Cited by 36
Recent advances in polymeric core–shell nanocarriers for targeted delivery of chemotherapeutic drugs
Yang, X., & Xie, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121094 · Cited by 33
Self‐Assembled Micelles Based on PEG‐Polypeptide Hybrid Copolymers for Drug Delivery
Hua, S., Li, Y., Liu, Y., Xiao, W., Li, C., Huang, F., Zhang, X., & Zhuo, R. (2009) · Macromolecular Rapid Communications · doi:10.1002/marc.200900473 · Cited by 37
Amphiphilic block copolymers–based micelles for drug delivery
Imran, M., Shah, M. R., & Shafiullah (2018) · Design and Development of New Nanocarriers · doi:10.1016/b978-0-12-813627-0.00010-7 · Cited by 35
Polymeric Micelles for the Delivery of Poorly Soluble Drugs
Biswas, S., Vaze, O. S., Movassaghian, S., & Torchilin, V. P. (2013) · Wiley eBooks · doi:10.1002/9781118444726.ch14 · Cited by 41
Hu, Q., van Gaal, E. V. B., Brundel, P., Ippel, H., Hackeng, T. M., Rijcken, C. J. F., Storm, G., Hennink, W. E., & Prakash, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.023 · Cited by 35
Mukai, H., Kato, K., Esaki, T., Ohsumi, S., Hozomi, Y., Matsubara, N., Hamaguchi, T., Matsumura, Y., Goda, R., Hirai, T., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0381-4 · Cited by 37
Self-citationCai, L., Qiu, N., Li, X., Luo, K., Chen, X., Yang, L., He, G., Wei, Y., & Chen, L. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.042 · Cited by 33
Guo, H., & Mi, P. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1988 · Cited by 37
Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors
Upponi, J. R., & Torchilin, V. P. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_1 · Cited by 43
Dai, Y., Wang, S., Shi, W., & Lang, M. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.08.011 · Cited by 33
Serras, A. S., Faustino, C. M. C., & Pinheiro, L. M. V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081047 · Cited by 35
Controlled release nanoplatforms for three commonly used chemotherapeutics
Costoya, J., Surnar, B., Kalathil, A. A., Kolishetti, N., & Dhar, S. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101043 · Cited by 34
Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging
Yasunaga, M., Manabe, S., Tsuji, A. B., Furuta, M., Ogata, K., Koga, Y., Saga, T., & Matsumura, Y. (2017) · Bioengineering · doi:10.3390/bioengineering4030078 · Cited by 39
Self-citationFonge, H., Lee, H., Reilly, R. M., & Allen, C. J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900201v · Cited by 34
Liu, G., Zhuang, W., Chen, X., Yin, A., Nie, Y., & Wang, Y. (2016) · Polymer · doi:10.1016/j.polymer.2016.08.012 · Cited by 31
Cancer Nanotechnology-An Excursion on Drug Delivery Systems
Sharma, M., Pandey, C., Sharma, N., Kamal, M. A., Sayeed, U., & Akhtar, S. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180720164015 · Cited by 32
Cheng, F., Guan, X., Cao, H., Su, T., Cao, J., Chen, Y., Cai, M., He, B., Gu, Z., & Luo, X. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.07.031 · Cited by 34
Wu, W., Jing, Zheng, Z., Huang, Liu, Hu, Liu, Wang, Yue, Y., & Tong (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s32620 · Cited by 30
Lynn, G. M., Laga, R., & Jewell, C. M. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114427 · Cited by 32
Histological study on side effects and tumor targeting of a block copolymer micelle on rats
Kawaguchi, T., Honda, T., Nishihara, M., Yamamoto, T., & Yokoyama, M. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.02.011 · Cited by 33
Self-citation
Metadata
- Authors
- Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T.
- Affiliations
- National Cancer Centre Japan (JP)
- Nippon Kayaku (Japan) (JP)
- NanoCarrier (Japan) (JP)
- Kanagawa Academy of Science and Technology (JP)
- The University of Tokyo (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-03-22
- Volume
- 92
- Issue
- 7
- Pages
- 1240-1246
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361981
- OpenAlex
- W2112927879
- Cited by
- 565
- References
- 23
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 18 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 29 · 2019: 21 · 2018: 27 · 2017: 36 · 2016: 41 · 2015: 50 · 2014: 40 · 2013: 29 · 2012: 33
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- paclitaxel, micellar nanoparticles, nanoparticle drug delivery, neurotoxicity, antitumour activity, pharmacokinetics, pharmacodynamics, block copolymer micelles, colorectal cancer, HT-29 xenograft, drug leakage, sustained drug release, metastatic solid tumors
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Chemistry, Pharmaceutical, Colonic Neoplasms, Humans, Nervous System, Transplantation, Heterologous, Paclitaxel, Area Under Curve, Nanostructures, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.